Neoadjuvant chemotherapy for operable breast cancer

DOI PDF Web Site 被引用文献1件
  • J S D Mieog
    Department of Surgery, Leiden University Medical Centre, Albinusdreef 2, 2300 RC Leiden, The Netherlands
  • J A van der Hage
    Department of Surgery, Leiden University Medical Centre, Albinusdreef 2, 2300 RC Leiden, The Netherlands
  • C J H van de Velde
    Department of Surgery, Leiden University Medical Centre, Albinusdreef 2, 2300 RC Leiden, The Netherlands

書誌事項

公開日
2007-08-13
権利情報
  • https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model
DOI
  • 10.1002/bjs.5894
公開者
Oxford University Press (OUP)

この論文をさがす

説明

<jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>Neoadjuvant chemotherapy for early breast cancer can avoid mastectomy by shrinkage of tumour volume. This review assesses the effectiveness of neoadjuvant chemotherapy on clinical outcome.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>All randomized trials comparing neoadjuvant and adjuvant chemotherapy for early breast cancer were reviewed systematically and meta-analyses were performed.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Fourteen studies randomizing 5500 women were eligible for analysis. Overall survival was equivalent in both groups. In the neoadjuvant group, the mastectomy rate was lower (relative risk 0·71 (95 per cent confidence interval (c.i.) 0·67 to 0·75)) without hampering local control (hazard ratio 1·12 (95 per cent c.i. 0·92 to 1·37)). Neoadjuvant chemotherapy was associated fewer adverse effects.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>Neoadjuvant chemotherapy is an established treatment option for early breast cancer.</jats:p> </jats:sec>

収録刊行物

被引用文献 (1)*注記

もっと見る

問題の指摘

ページトップへ